ABVC Biopharma Inc
NASDAQ:ABVC
Gross Margin
ABVC Biopharma Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
ABVC Biopharma Inc
NASDAQ:ABVC
|
76.3m USD |
100%
|
|
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
633.6T EUR | N/A | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
168.7B USD |
18%
|
|
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD |
16%
|
|
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
84.1B Zac |
66%
|
|
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
67.5B USD |
74%
|
|
| US |
|
Coupang Inc
F:788
|
50.6B EUR |
30%
|
|
| CH |
G
|
Galderma Group AG
SIX:GALD
|
34.7B CHF |
69%
|
|
| US |
|
Symbotic Inc
NASDAQ:SYM
|
41B USD |
17%
|
|
| US |
R
|
Reddit Inc
NYSE:RDDT
|
37.7B USD |
91%
|
|
| US |
C
|
Circle Internet Group Inc
NYSE:CRCL
|
34.4B USD |
0%
|
ABVC Biopharma Inc
Glance View
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 28 full-time employees. The company went IPO on 2004-11-09. The firm develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Its pipeline includes ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1601, ABV-1701 and ABV-2002. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). The company is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1501 is a combination therapy for triple negative breast cancer (TNBC). ABV-1701 is a vitreous substitute for vitrectomy. ABV-1703 is a drug for advanced inoperable or metastatic pancreatic cancer. ABV-2002 is a corneal storage media consisting of a specific polymer formulated to protect ocular tissues from osmolarity.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on ABVC Biopharma Inc's most recent financial statements, the company has Gross Margin of 99.9%.
You don't have any saved screeners yet